On June 14, 2022, Boehringer Ingelheim, a leading research-driven biopharmaceutical company, announced the signing of an option to acquire Trutino Biosciences Inc., a San Diego-based pre-clinical stage biotech company dedicated to the discovery and development of next-generation cytokine therapies to treat immuno-oncology and autoimmune diseases. Wilson Sonsini Goodrich & Rosati advised Trutino Biosciences in the transaction.

Under the agreement, Boehringer Ingelheim reserves the right to purchase all shares of Trutino Biosciences once specified program milestones have been achieved within a given timeframe. Until that time, Trutino will continue to operate as an independent company, with the existing fruitful strategic partnership and collaboration agreement between the companies continuing uninterrupted.

The Wilson Sonsini team that represented Trutino Biosciences in the transaction includes Ian Edvalson, Martin Waters, Benjamin Capps, and Tim Conroy.

For more information, please see Boehringer Ingelheim's press release. Further coverage can be found on BioSpace.